文献速递脊柱关节炎

在英国的初级保健银屑病人群中加强监测以检出银屑病关节炎:TUDOR 试验结果

Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

TUDOR 是一项多中心、前瞻性、平行组整群随机对照试验,在初级保健银屑病人群中比较加强监测与标准诊疗对银屑病关节炎(PsA)患者 24 个月时身体功能的影响。共 2225 例注册,加强监测组 1123 例、标准诊疗组 1102 例;确诊 PsA 的主要分析人群 87 例(加强监测组 64 例、标准诊疗组 23 例)。24 个月时主要结局无证据显示两组存在差异(P=0.66),试验对预设疗效检验把握度不足。

要点

  • 确诊 PsA 的主要分析人群共 87 例:加强监测组 64 例,标准诊疗组 23 例。
  • 24 个月时达到 HAQ-DI 评分为 0 的校正 OR 为 0.64(95%CI 0.17,2.38)。
  • 两组差异无统计学意义(P=0.66),原文认为试验对预设疗效检验把握度不足。

核心结论

  • 原文认为该试验对证明预设疗效把握度不足;在银屑病患者中,无证据表明初级保健中加强监测早期诊断 PsA 较标准诊疗改变 24 个月时的身体功能。

研究设计与样本

  • 多中心、前瞻性、平行组整群随机对照试验,在初级保健银屑病患者中开展。
  • 共 135 家全科诊所的 2225 例参与者注册:加强监测组 1123 例,标准诊疗组 1102 例。
  • 筛查疑似炎性关节炎者转诊评估 PsA:加强监测组在基线、12 个月和 24 个月评估,标准诊疗组在 24 个月评估。
  • 主要结局为注册后 24 个月时确诊 PsA 参与者的 HAQ 残疾指数(HAQ-DI)。
  • 主要分析人群为 87 例确诊 PsA 参与者:加强监测组 64 例,标准诊疗组 23 例。

主要发现

  • 注册后 24 个月时达到 HAQ-DI 评分为 0 的校正 OR 为 0.64(95%CI 0.17,2.38),加强监测组相比标准诊疗组。
  • 注册后 24 个月时达到较高(非零)HAQ-DI 评分的校正 OR 为 1.12(95%CI 0.67,1.86),加强监测组相比标准诊疗组。
  • 原文指出两组间无差异证据(P=0.66)。

局限性

  • 原文指出该试验对证明预设疗效把握度不足。
  • 原文结论称无证据表明加强监测早期诊断 PsA 较标准诊疗改变 24 个月时的身体功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our objective was to determine whether early detection of undiagnosed PsA in a primary care psoriasis population improves outcome in physical function at 24 months post-registration. METHODS: A multicentre, prospective, parallel group cluster randomized controlled trial in patients with psoriasis was conducted. Participants with suspected inflammatory arthritis on screening were referred for an assessment of PsA [enhanced surveillance (ES) arm: at baseline, and 12 and 24 months; standard care (SC) arm: at 24 months]. The primary outcome measure was the HAQ Disability Index (HAQ-DI) at 24 months post-registration in participants diagnosed with PsA. RESULTS: A total of 2225 participants across 135 general practitioner practices registered: 1123 allocated to ES and 1102 to SC. The primary analysis population consisted of 87 participants with a positive diagnosis of PsA: 64 in ES, 23 in SC. The adjusted odds ratio (OR) for achieving a HAQ-DI score of 0 at 24 months post-registration in ES compared with SC was 0.64 [95% CI (0.17, 2.38)], and the adjusted OR of achieving a higher (non-zero) HAQ-DI score at 24 months post-registration in ES relative to SC arm was 1.12 (95% CI 0.67, 1.86), indicating no evidence of a difference between the two treatment groups (P = 0.66). CONCLUSION: The trial was underpowered for demonstrating the prespecified treatment effect; in patients with psoriasis there was no evidence that early diagnosis of PsA by ES in primary care changes physical function at 24 months compared with SC. CLINICAL TRIAL REGISTRATION: The TUDOR trial is registered as ISRCTN38877516.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. McHugh N, Tillett W, Helliwell P, et al. Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial. Rheumatology (Oxford). 2025. PMID: 39037920. doi:10.1093/rheumatology/keae374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。